|
1
|
Jia WH, Huang QH, Liao J, Ye W, Shugart
YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, et al: Trends in
incidence and mortality of nasopharyngeal carcinoma over a 20–25
year period (1978/1983-2002) in Sihui and Cangwu counties in
southern China. BMC Cancer. 6:1782006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li
JX and Lu TX: Long-term outcomes of early-stage nasopharyngeal
carcinoma patients treated with intensity-modulated radiotherapy
alone. Int J Radiat Oncol Biol Phys. 82:327–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiao WW, Han F, Lu TX, Chen CY, Huang Y
and Zhao C: Treatment outcomes after radiotherapy alone for
patients with early-stage nasopharyngeal carcinoma. Int J Radiat
Oncol Biol Phys. 74:1070–1076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou J, Wang L, Xu X, Tu Y, Qin S and Yin
Y: Antitumor activity of Endostar combined with radiation against
human nasopharyngeal carcinoma in mouse xenograft models. Oncol
Lett. 4:976–980. 2012.PubMed/NCBI
|
|
5
|
Lee AW, Ng WT, Hung WM, Choi CW, Tung R,
Ling YH, Cheng PT, Yau TK, Chang AT, Leung SK, et al: Major late
toxicities after conformal radiotherapy for nasopharyngeal
carcinoma-patient- and treatment-related risk factors. Int J Radiat
Oncol Biol Phys. 73:1121–1128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akervall J, Nandalur S, Zhang J, Qian CN,
Goldstein N, Gyllerup P, Gardinger Y, Alm J, Lorenc K, Nilsson K,
et al: A novel panel of biomarkers predicts radioresistance in
patients with squamous cell carcinoma of the head and neck. Eur J
Cancer. 50:570–581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arichi H, Kimura Y, Okuda H, Baba K,
Kozawa M and Arichi S: Effects of stilbene components of the roots
of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem
Pharm Bull (Tokyo). 30:1766–1770. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soleas GJ, Diamandis EP and Goldberg DM:
Resveratrol: a molecule whose time has come? and gone? Clin
Biochem. 30:91–113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bradamante S, Barenghi L and Villa A:
Cardiovascular protective effects of resveratrol. Cardiovasc Drug
Rev. 22:169–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Das S and Das DK: Anti-inflammatory
responses of resveratrol. Inflamm Allergy Drug Targets. 6:168–173.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de la Lastra CA and Villegas I:
Resveratrol as an anti-inflammatory and anti-aging agent:
mechanisms and clinical implications. Mol Nutr Food Res.
49:405–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Z, Liu B, E C, Liu J, Zhang Q, Liu J,
Chen N, Chen R and Zhu R: Resveratrol inhibits the proliferation of
human melanoma cells by inducing G1/S cell cycle arrest and
apoptosis. Mol Med Rep. 11:400–404. 2015.PubMed/NCBI
|
|
14
|
Yu XD, Yang JL, Zhang WL and Liu DX:
Resveratrol inhibits oral squamous cell carcinoma through induction
of apoptosis and G2/M phase cell cycle arrest. Tumour Biol.
37:2871–2877. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trung L Quoc, Espinoza JL, Takami A and
Nakao S: Resveratrol induces cell cycle arrest and apoptosis in
malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One.
8:e551832013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fowler JF: The linear-quadratic formula
and progress in fractionated radiotherapy. Br J Radiol. 62:679–694.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong JV, Dong P, Nevins JR, Mathey-Prevot
B and You L: Network calisthenics: control of E2F dynamics in cell
cycle entry. Cell Cycle. 10:3086–3094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee AW, Sze WM, Au JS, Leung SF, Leung TW,
Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al: Treatment results
for nasopharyngeal carcinoma in the modern era: the Hong Kong
experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Das DK and Maulik N: Resveratrol in
cardioprotection: a therapeutic promise of alternative medicine.
Mol Interv. 6:36–47. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pervaiz S and Holme AL: Resveratrol: its
biologic targets and functional activity. Antioxid Redox Signal.
11:2851–2897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Ma S, Meng N, Yao N, Zhang K, Li
Q, Zhang Y, Xing Q, Han K, Song J, et al: Resveratrol exerts
dosage-dependent effects on the self-renewal and neural
differentiation of hUC-MSCs. Mol Cells. 39:418–425. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
García-Zepeda SP, García-Villa E,
Díaz-Chávez J, Hernández-Pando R and Gariglio P: Resveratrol
induces cell death in cervical cancer cells through apoptosis and
autophagy. Eur J Cancer Prev. 22:577–584. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong W, Yin A, Mao X, Zhang W, Huang H
and Zhang X: Resveratrol suppresses human glioblastoma cell
migration and invasion via activation of RhoA/ROCK signaling
pathway. Oncol Lett. 11:484–490. 2016.PubMed/NCBI
|
|
25
|
Kma L: Synergistic effect of resveratrol
and radiotherapy in control of cancers. Asian Pac J Cancer Prev.
14:6197–6208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang Y, DeMarco VG and Nicholl MB:
Resveratrol enhances radiation sensitivity in prostate cancer by
inhibiting cell proliferation and promoting cell senescence and
apoptosis. Cancer Sci. 103:1090–1098. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao HF, Kuo CD, Yang YC, Lin CP, Tai HC,
Chen YY and Chen YJ: Resveratrol enhances radiosensitivity of human
non-small cell lung cancer NCI-H838 cells accompanied by inhibition
of nuclear factor-kappa B activation. J Radiat Res (Tokyo).
46:387–393. 2005. View Article : Google Scholar
|
|
28
|
Lu KH, Chen YW, Tsai PH, Tsai ML, Lee YY,
Chiang CY, Kao CL, Chiou SH, Ku HH, Lin CH, et al: Evaluation of
radiotherapy effect in resveratrol-treated medulloblastoma cancer
stem-like cells. Childs Nerv Syst. 25:543–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaussepied M and Ginsberg D:
Transcriptional regulation of AKT activation by E2F. Mol Cell.
16:831–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Korotayev K, Chaussepied M and Ginsberg D:
ERK activation is regulated by E2F1 and is essential for
E2F1-induced S phase entry. Cell Signal. 20:1221–1226. 2008.
View Article : Google Scholar : PubMed/NCBI
|
